Several other research firms also recently issued reports on CRSP. BidaskClub upgraded shares of Crispr Therapeutics from a hold rating to a buy rating in a research note on Friday, November 15th. William Blair raised shares of Crispr Therapeutics from a market perform rating to an outperform rating in a research report on Tuesday, November 19th. TheStreet raised Crispr Therapeutics from a d rating to a c rating in a research report on Monday, October 28th. BTIG Research upped their target price on Crispr Therapeutics from $51.00 to $59.00 and gave the stock a positive rating in a research report on Tuesday, July 30th. Finally, Needham & Company LLC reiterated a buy rating and set a $62.00 price objective on shares of Crispr Therapeutics in a research note on Wednesday, July 31st. Two investment analysts have rated the stock with a sell rating, two have assigned a hold rating, thirteen have issued a buy rating and one has assigned a strong buy rating to the company. The stock currently has a consensus rating of Buy and a consensus target price of $69.54.
Crispr Therapeutics stock opened at $72.37 on Tuesday. Crispr Therapeutics has a 1 year low of $22.22 and a 1 year high of $74.00. The firm has a 50 day moving average price of $54.81 and a 200 day moving average price of $47.38. The company has a market cap of $4.00 billion, a price-to-earnings ratio of -21.04 and a beta of 3.30. The company has a debt-to-equity ratio of 0.06, a quick ratio of 8.32 and a current ratio of 8.32.
Crispr Therapeutics (NASDAQ:CRSP) last issued its earnings results on Monday, October 28th. The company reported $2.40 earnings per share for the quarter, topping the consensus estimate of ($0.95) by $3.35. Crispr Therapeutics had a negative return on equity of 2.60% and a negative net margin of 5.30%. The business had revenue of $211.93 million for the quarter, compared to analyst estimates of $6.32 million. Sell-side analysts predict that Crispr Therapeutics will post 0.65 EPS for the current year.
In other news, President Rodger Novak sold 33,618 shares of Crispr Therapeutics stock in a transaction that occurred on Tuesday, November 19th. The stock was sold at an average price of $70.00, for a total value of $2,353,260.00. Following the completion of the transaction, the president now owns 33,618 shares in the company, valued at approximately $2,353,260. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, Director Pablo J. Cagnoni sold 7,500 shares of the company’s stock in a transaction that occurred on Tuesday, November 19th. The shares were sold at an average price of $62.00, for a total value of $465,000.00. Following the sale, the director now directly owns 7,500 shares in the company, valued at $465,000. The disclosure for this sale can be found here. Insiders sold a total of 56,118 shares of company stock valued at $3,620,760 in the last three months. Insiders own 21.40% of the company’s stock.
A number of hedge funds have recently added to or reduced their stakes in CRSP. Xact Kapitalforvaltning AB bought a new position in shares of Crispr Therapeutics in the 2nd quarter worth about $207,000. Commonwealth Equity Services LLC increased its position in Crispr Therapeutics by 5.9% in the second quarter. Commonwealth Equity Services LLC now owns 17,815 shares of the company’s stock worth $839,000 after buying an additional 986 shares during the period. Buckley Wealth Management LLC acquired a new stake in Crispr Therapeutics in the second quarter worth $236,000. Carnegie Capital Asset Management LLC bought a new stake in Crispr Therapeutics in the second quarter valued at $1,064,000. Finally, Moody Aldrich Partners LLC bought a new stake in Crispr Therapeutics in the second quarter valued at $1,838,000. Hedge funds and other institutional investors own 49.81% of the company’s stock.
Crispr Therapeutics Company Profile
CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9) gene-editing platform in Switzerland. Its lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from dependent beta thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells.
Featured Article: How is the S&P 500 index different from the DJIA?
Receive News & Ratings for Crispr Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.